Abstract
Breast cancer (BC) is the leading cause of death among women all over the world. Estrogen receptor (ER) based therapy is one of the major approaches to target BC and is associated with various problems such as primary as well as secondary resistance. ER signaling is a complex pathway as many factors are involved; including several types of ERs and their associated co-regulators. Increasing understanding of ER signals results in new approaches targeting towards BCs. In this context, ER co-regulators have been explored and many modulators of ER co-regulators have been found out. EGFR and mTOR pathways also have significant impact on BC endocrine therapy because of the complex crosstalk mechanism which is responsible for primary and secondary resistance. Triple negative breast cancer (TNBC) is majorly associated with BRCA mutations. Currently there is no approved targeted therapy available in such form of cancer. Although PARP inhibitors seem to be suitable candidates for it. The present review is focused on the current scenario of ER, EGFR, as well as mTOR signaling target therapy. We have also discussed the current status of PARP inhibitors in BC chemotherapy.
Keywords: Breast cancer, chemotherapy, crosstalk, resistance, targeting.
Anti-Cancer Agents in Medicinal Chemistry
Title:Drug Target Strategies in Breast Cancer Treatment: Recent Developments
Volume: 14 Issue: 10
Author(s): Mayank and Vikas Jaitak
Affiliation:
Keywords: Breast cancer, chemotherapy, crosstalk, resistance, targeting.
Abstract: Breast cancer (BC) is the leading cause of death among women all over the world. Estrogen receptor (ER) based therapy is one of the major approaches to target BC and is associated with various problems such as primary as well as secondary resistance. ER signaling is a complex pathway as many factors are involved; including several types of ERs and their associated co-regulators. Increasing understanding of ER signals results in new approaches targeting towards BCs. In this context, ER co-regulators have been explored and many modulators of ER co-regulators have been found out. EGFR and mTOR pathways also have significant impact on BC endocrine therapy because of the complex crosstalk mechanism which is responsible for primary and secondary resistance. Triple negative breast cancer (TNBC) is majorly associated with BRCA mutations. Currently there is no approved targeted therapy available in such form of cancer. Although PARP inhibitors seem to be suitable candidates for it. The present review is focused on the current scenario of ER, EGFR, as well as mTOR signaling target therapy. We have also discussed the current status of PARP inhibitors in BC chemotherapy.
Export Options
About this article
Cite this article as:
Mayank and Jaitak Vikas, Drug Target Strategies in Breast Cancer Treatment: Recent Developments, Anti-Cancer Agents in Medicinal Chemistry 2014; 14 (10) . https://dx.doi.org/10.2174/1871520614666140407114853
DOI https://dx.doi.org/10.2174/1871520614666140407114853 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
MicroRNAs in Lung Cancer and Lung Cancer Bone Metastases: Biomarkers for Early Diagnosis and Targets for Treatment
Recent Patents on Anti-Cancer Drug Discovery The Role of Downstream Signaling Pathways of the Epidermal Growth Factor Receptor for Artesunates Activity in Cancer Cells
Current Cancer Drug Targets Conventional Anticancer Therapeutics and Telomere Maintenance Mechanisms
Current Pharmaceutical Design The Role of DNA Methylation in the Pathogenesis and Treatment of Cancer
Current Clinical Pharmacology Signal Transduction Therapy for Cancer - Whither Now?
Current Signal Transduction Therapy General Molecular Biology and Architecture of Nuclear Receptors
Current Topics in Medicinal Chemistry Melatonin as a Selective Estrogen Enzyme Modulator
Current Cancer Drug Targets Cyclin D1 Gene Silencing by siRNA in Ex Vivo Human Tissue Cultures
Current Drug Delivery TGFb and its Smad Connection to Cancer
Current Genomics Targeted Therapy for Advanced Urothelial Cancer of the Bladder: Where Do We Stand?
Anti-Cancer Agents in Medicinal Chemistry Meet Our Editorial Board Member
Current Enzyme Inhibition Application of Remote Ischemic Preconditioning in Patients Undergoing Chemotherapy with Anthracyclines
Current Enzyme Inhibition Chitinases: Biomarkers for Human Diseases
Protein & Peptide Letters Criteria of Evidence to Move Potential Chemopreventive Agents into Late Phase Clinical Trials
Current Drug Targets Alpha-1-Adrenergic Receptor Blockade Modifies Insulin-Regulated Aminopeptidase (IRAP) Activity in Rat Prostate and Modulates Oxytocin Functions
Drug Metabolism Letters Therapeutic Drugs in Bone Loss-Associated Disorders: Clinical Outcomes and Challenges
Current Drug Targets Random Start Ovarian Stimulation for Oocyte or Embryo Cryopreservation in Women Desiring Fertility Preservation Prior to Gonadotoxic Cancer Therapy
Current Pharmaceutical Biotechnology CORAL: Classification Model for Predictions of Anti-Sarcoma Activity
Current Topics in Medicinal Chemistry KiSS1-Induced GPR54 Signaling Inhibits Breast Cancer Cell Migration and Epithelial-Mesenchymal Transition via Protein Kinase D1
Current Molecular Medicine The Application of Chitosan and Its Derivatives as Nanosized Carriers for the Delivery of Chemical Drugs and Genes or Proteins
Current Drug Targets